A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura

Haematologica

Volumn 93, Issue 7, 2008, Pages 1113-1115

  Emilia, Giovanni ^a,b   Luppi, Mario ^a   Morselli, Monica ^a   Forghieri, Fabio ^a   Potenza, Leonardo ^a   Torelli, Giuseppe ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cyclosporine; Low dose; Refractory ITP; Safety

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN; DANAZOL; DEXAMETHASONE; ELTROMBOPAG; RITUXIMAB;

CANDIDIASIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; HELICOBACTER INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LOW DRUG DOSE; REFRACTORY THROMBOCYTOPENIA; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CYCLOSPORINE; FEMALE; HEMATOLOGY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC; RISK; TREATMENT OUTCOME;

EID: 46849091977     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12741     Document Type: Letter

References (12)

1. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4: 1664-72.
2. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
3. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007;110:3526-31.
4. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of Chronic Idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.
5. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8.
6. Kappers-Klunne MC, van't Veer MB. CyclosporinA for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121-5.
7. Perrotta S, Amendola G, Locatelli F, Conte ML, Rossi F, d'Urzo G, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003;121:143-7.
8. Emilia G, Morselli M, Luppi M, Longo G, Marasca R, Gandini G, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002;99:1482-5.
9. Zver S, Zupan IP, Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. Int J Hematol 2006;83:238-42.
10. Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP. Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999; 21:77-9.
11. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2005;132:125-37.
12. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007;110:3833-41.